Smart Immune SAS
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT) in adult and pediatric patients with hematological malignancies.
Inclusion Criteria: Group A (adults): 1. Adult patients affected by: * Acute leukemia (AML, ALL) defined as: * Acute Myeloid Leukemia (AML): * High risk AML in CR1; any adverse genetic abnormality, secondary or therapy related AML excluding good risk genetic abnormalities * Chemo-refractory relapse (MRD+) * ≥ CR2 * Acute Lymphoblastic Leukemia (ALL): * Chemo-refractory relapse (MRD+) * High risk ALL in CR1; Philadelphia (like) or any poor risk feature * ≥ CR2 * Acute leukemia of ambiguous lineage: * ≥ CR1 with a minimal…
Injection of T cell progenitors at \[Day 4-Day 10\] after T cell depleted allogeneic HSCT
Arctuva estimate
Verify or correct the compensation shown for this listing.